---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018093"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:45:38.293549+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market

## Summary
- Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
- Subject to one-year Mandatory Panel Monitor; if equity rule breached, no additional time to regain compliance but hearing available.
- Common stock (BIAF) and warrants (BIAFW) continue trading on Nasdaq Capital Market.
- CEO Maria Zannes: regaining compliance allows focus on CyPath Lung test and building shareholder value.

## SEC filing metadata
- accession: 0001493152-25-018093
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/0001493152-25-018093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018093
- JSON: https://secwatch.observer/filing/0001493152-25-018093.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.